Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGOS first-line ES-SCLC trial of BMS-986489 plus chemotherapy versus atezolizumab plus chemotherapy
NL-OMON60345Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bms-986012 + nivolumab, Atigotatug, nivolumab and atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival. Started Apr 2025; status: active, not recruiting.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON60345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60345.